Rationale: Interstitial lung disease (ILD) occurs in Japanese patients with non–small cell
lung cancer (NSCLC) receiving gefitinib. Objectives: To elucidate risk factors for ILD in …

A high incidence of interstitial lung disease (ILD) has been reported in patients with non-
small cell lung cancer (NSCLC) treated with gefitinib in Japan. We retrospectively analyzed …

Purpose Interstitial lung disease (ILD) is a serious adverse effect of gefitinib, but its
prevalence and risk factors remain largely unknown. We examined the prevalence of and …

Drug-associated interstitial lung disease (ILD) is not uncommon, with diverse patterns
ranging from benign infiltrates to the potentially fatal acute respiratory distress syndrome. As …

Objectives Gefitinib and erlotinib are oral epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitors (TKIs) widely used in advanced non-small cell lung cancer (NSCLC) …

Introduction It is unknown what type of interstitial lung disease (ILD) has high risk for
chemotherapy-related exacerbation of ILD. We investigated the risk of exacerbation of ILD …

The association between lung cancer (LC) and interstitial lung disease (ILD) can be
explained by the shared risk factors like smoking and physiopathology of fibrogenesis and …

Since the approval of the first molecularly targeted tyrosine kinase inhibitor (TKI), imatinib, in
2001, TKIs have heralded a new era in the treatment of many cancers. Among their …

Gefitinib (Iressa™) is an epidermal growth factor receptor tyrosine kinase inhibitor that has
been approved for the treatment of lung cancer in Japan, however, after marketing several …

Interstitial lung disease (ILD) occurrence and risk factors were investigated in the Japanese
non‐small‐cell lung cancer, post‐marketing, large‐scale surveillance study, POLARSTAR …